

UltraGRO[™]–Advanced Cell Culture Supplement

Description

UltraGRO[™]–Advanced cell culture supplement is a non-xenogeneic, animal serum-free, media supplement for replacing FBS (fetal bovine serum) to support cell expansion from research through clinical trials to commercial use. UltraGRO[™]–Advanced contains abundant growth factors and cytokines necessary for research or industrial cell growth and proliferation of multiple cell types (e.g. MSCs).



Product	Catalog No.	Spec.	Storage	Shelf Life*
UltraGRO [™] –Advanced	HPCFDCRL05	50mL		
(Research grade)	HPCFDCRL10	100mL		
	HPCFDCRL50	500mL	Store at -20°C	24 months
UltraGRO [™] –Advanced	HPCFDCGL05	50mL	Store at -20 C	24 months
(GMP grade)	HPCFDCGL10	100mL		
	HPCFDCGL50	500mL		

^{*}Shelf life duration is determined from Date of Manufacture, continuously stored frozen in original bottle.

Intended use

For human ex-vivo tissue and cell culture processing applications.

Important information

Insoluble particles may form in thawed UltraGRO[™]—Advanced cell culture supplement. Published research has shown that particles will not alter the performance of the product.

Safety information

- Follow the handling instructions outlined in the Material Safety Data Sheets (MSDSs). Wear appropriate protective eyewear, clothing, and gloves.
- Human origin materials are non-reactive (donor level) for anti-HIV 1 & 2, anti-HCV and HBsAg. Handle in accordance with established bio-safety practices.

MSC culture conditions

Media:

Complete medium is comprised of a basal media (e.g. α -MEM or other supportive media) and

UltraGRO[™]–Advanced **Culture type:** Adhesion

Culture vessels: Cell culture plates, T-flasks, G-Rex

flasks or cell culture bags

Temperature range: 36°C to 38°C

Incubator atmosphere: Humidified atmosphere of 4–6% CO₂. Ensure that proper gas exchange is achieved

in culture vessels.

Precipitation in Cell Culture

- Insoluble particles may form in thawed UltraGROTM-Advanced, it is recommended to remove particles by centrifuge at 3,400 xg for 3~5 minutes.
- Filtering the completed medium (e.g. 5%), after UltraGROTM—Advanced is diluted in the basal medium, will not affect UltraGROTM—Advanced supplemented cell culture performance.
 However, 0.22 μm filtering is NOT recommended for 100% concentrate UltraGROTM—Advanced, as this may reduce 5% UltraGROTM—Advanced cell culture performance.
- Repeated freeze-thaw cycles should be avoided as they may cause an increase in insoluble particles and resulting potential decrease in UltraGROTM—Advanced performance.

Protocol

- UltraGROTM—Advanced shows optimal growth of MSC at 5% (v/v) in typical cell culture media, i.e. α -MEM, which contains 2mM L-Glutamine as final concentrate.
- We recommend seeding MSCs at approximately $3\times10^3 \sim 6\times10^3$ per cm².
- For UltraGRO[™]-Advanced has been fibrinogen-depleted and does not require the addition of heparin in the cell culture media.

Storage

UltraGROTM–Advanced product is most stable when stored frozen until needed. The recommended storage temperature is -20°C or -80°C. Thaw frozen UltraGROTM–Advanced product in 37°C water bath before use. Once UltraGROTM–Advanced product is thawed, it is recommended to fully use for completed medium preparation (e.g. 5%) the same day, or to divide it into single-use aliquots and store unused aliquots at -20°C or -80°C.

Cell Lines

Bone marrow mesenchymal stem cells Adipose tissue derived mesenchymal stem cells Umbilical cord derived mesenchymal stem cells Other mesenchymal stem cells

References

- Copland IB, Garcia MA, Waller EK, Roback JD, Galipeau J. <u>The effect of platelet lysate</u> <u>fibrinogen on the functionality of MSCs in</u> <u>immunotherapy</u>. *Biomaterials*. 2013;34(32): 7840-50.
- US FDA IND14825, Autologous Bone Marrow Derived Mesenchymal Stromal Cells for <u>Crohn's</u> Disease.
- US FDA IND16191, Autologous Mesenchymal stem cells for GvHD.
- US FDA IND14924, Percutaneous Image
 Guided Delivery of Autologous Bone Marrow
 Derived Mesenchymal Stem Cells for the
 Treatment of <u>Symptomatic Degenerated</u>
 Intervertebral Disc Disease.
- US FDA IND15970, Autologous MSCs islet autograft via portal vein infusion to reduce onset of diabetes and improve glycemic control in patients with <u>chronic pancreatitis</u>.

For Technical and Ordering information, contact:

AventaCell BioMedical Co., Ltd., 575 Fourteenth Street, NW Atlanta, GA 30318 USA (Manufacture)

Website: <u>www.atcbiomed.com</u> Email: <u>sales@atcbiomed.com</u>

For additional technical information such as Safety Data Sheets (SDS), Certificates of Analysis, visit www.atcbiomed.com. For further assistance, email sales@atcbiomed.com.

© 2015 AventaCell BioMedical Co., Ltd. All rights reserved. All trademarks herein are marks of AventaCell group and its subsidiaries.

DISCLAIMER: TO THE EXTENT ALLOWED BY LAW, AVENTACELL BIOMEDICAL AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING YOUR USE OF IT. www.atcbiomed.com